Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 11/20 | 0.34 |
| ▸ | ABL1 | P00519 | 4/20 | 0.33 |
| ▸ | SRC | P12931 | 4/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540179 | 0.81 | NUDT1 (0.36) | NUDT1TNK2ABL1SRCBTK | |
| SCHEMBL20810656 | 0.81 | NUDT1 (0.36) | NUDT1TNK2ABL1SRCBTK | |
| SCHEMBL23044547 | 0.79 | BTK (0.48) | NUDT1TNK2ABL1SRCBTK | |
| SCHEMBL17893144 | 0.75 | NUDT1 (0.34) | NUDT1TNK2ABL1SRCBTK | |
| SCHEMBL18099733 | 0.75 | ABL1 (0.53) | NUDT1TNK2ABL1SRCBTK | |
| SCHEMBL31330580 | 0.75 | TNK2 (0.40) | TNK2BTK | |
| SCHEMBL23111989 | 0.75 | TNK2 (0.51) | TNK2ABL1SRCBTK | |
| SCHEMBL31330632 | 0.75 | TNK2 (0.51) | NUDT1TNK2ABL1SRCBTK | |
| SCHEMBL18849916 | 0.73 | ABL1 (0.43) | NUDT1TNK2ABL1SRCBTK | |
| SCHEMBL18849914 | 0.73 | ABL1 (0.43) | NUDT1TNK2ABL1SRCBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481733-B2 | Substituted imidazopyr- and imidazotri-azines | OSI Pharmaceuticals, LLC (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2283020-B1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARM INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2283020-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009143051-A1 | SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | OSI PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286768-A1 | SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES | ABL1, TPMT, CYP2C19 | NUDT1 777/4885TNK2 2837/4885ABL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.